<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A 76-year-old patient is described in whom a severe, life-threatening tardive <z:hpo ids='HP_0100660'>dyskinesia</z:hpo> developed after oral administration of approximately 2 mg of <z:chebi fb="6" ids="5613">haloperidol</z:chebi> per day for 4 weeks </plain></SENT>
<SENT sid="1" pm="."><plain>The patient's strong genetic predisposition for <z:e sem="disease" ids="C0024408" disease_type="Disease or Syndrome" abbrv="MJD|SCA3">Joseph disease</z:e> may have potentiated both the development and the severity of the tardive <z:hpo ids='HP_0100660'>dyskinesia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Withdrawal of <z:chebi fb="0" ids="35476">neuroleptic agents</z:chebi> accompanied by aggressive treatment with <z:chebi fb="0" ids="28487">reserpine</z:chebi> resulted in a complete recovery over 5 weeks </plain></SENT>
<SENT sid="3" pm="."><plain>The clinical and pathologic characteristics of <z:e sem="disease" ids="C0024408" disease_type="Disease or Syndrome" abbrv="MJD|SCA3">Joseph disease</z:e> and tardive <z:hpo ids='HP_0100660'>dyskinesia</z:hpo> are compared </plain></SENT>
</text></document>